Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.

Alessandro M. Vannucchi, MD, Elisabetta Antonioli, MD, Alessandro Pancrazzi, BiSc, Paola Guglielmelli, MD, Simonetta Di Lollo, MD, Renato Alterini, MD, Vittoria Guerini, BiSc, Gianna Baroni, BiSc, Alessandro Rambaldi, MD, Alberto Bosi, MD, Tiziano Barbui, MD

Blood (2007) 110 (11): 678.

https://doi.org/10.1182/blood.V110.11.678.678

Published: 2007

Journal Articles

Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.

Luigi Rigacci, MD, Luca Nassi, MD, Simonetta di Lollo, MD, Benedetta Puccini, MD, Morena Doria, MD, Silvia Mappa, MD, Gloria Capaccioli, Renato Alterini, MD, Valentina Carrai, MD, Alberto Bosi, MD

Blood (2007) 110 (11): 4401.

https://doi.org/10.1182/blood.V110.11.4401.4401

Published: 2007

Journal Articles

First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.

Luigi Rigacci, MD, Marco Puccioni, MD, Luca Nassi, MD, Silvia Mappa, MD, Cinzia Mazzini, MD, Renato Alterini, MD, Valentina Carrai, MD, Ennio Polito, MD, Alberto Bosi, MD

Blood (2006) 108 (11): 4712.

https://doi.org/10.1182/blood.V108.11.4712.4712

Published: 2006

Journal Articles

Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.

Luigi Rigacci, MD, Silvia Mappa, MD, Luca Nassi, MD, Renato Alterini, MD, Valentina Carrai, MD, Franco Bernardi, MD, Alberto Bosi, MD

Blood (2006) 108 (11): 4685.

https://doi.org/10.1182/blood.V108.11.4685.4685

Published: 2006

Journal Articles

Intensified Chop (CHOP14) Plus Rituximab in the Treatment of Elderly Patients with Aggressive and High Risk Non Hodgkin’s Lymphoma (NHL).

Luigi Rigacci, MD, Luca Nassi, MD, Renato Alterini, MD, Valentina Carrai, MD, Franco Bernardi, MD, Varesco Martini, MD, Paolo Bernardeschi, MD, Giovanni Longo, MD, Alberto Bosi, MD

Blood (2004) 104 (11): 4577.

https://doi.org/10.1182/blood.V104.11.4577.4577

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.

Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.

First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.

Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.

Intensified Chop (CHOP14) Plus Rituximab in the Treatment of Elderly Patients with Aggressive and High Risk Non Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Update search

The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.

Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.

First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.

Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.

Intensified Chop (CHOP14) Plus Rituximab in the Treatment of Elderly Patients with Aggressive and High Risk Non Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only